Applications: |
CLIA |
Reactivity: |
Human |
Note: |
FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS. |
Sensitivity: |
9.38pg/mL |
Detection Limit: |
15.63~1000pg/mL |
Short Description: |
This human OLFM4 kit is a highly sensitive in-vitro chemiluminescent immunoassay for the measurement of trace amounts of analytes. |
Storage Instruction: |
If unopened the kit may be stored at 2-8°C for up to 1 month. If the kit will not be used within 1 month, store the components separately, according to the component table in the manual. |
Assay Time: |
3.5h |
Detection: |
Chemiluminescence |
Gene Symbol: |
OLFM4 |
Gene ID: |
10562 |
Uniprot ID: |
OLFM4_HUMAN |
Specificity: |
This kit recognizes Human OLFM4 in samples. No significant cross-reactivity or interference between Human OLFM4 and analogues was observed. |
Sample Type: |
Serum, plasma and other biological fluids |
Tissue Specificity | Expressed during myeloid lineage development. Much higher expression in bone marrow neutrophils than in peripheral blood neutrophils (at protein level). Strongly expressed in the prostate, small intestine and colon and moderately expressed in the bone marrow and stomach. Overexpressed in some pancreatic cancer tissues. |
Post Translational Modifications | N-glycosylated. |
Function | May promote proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines, inhibits cell growth and induces cell differentiation and apoptosis. May play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Facilitates cell adhesion, most probably through interaction with cell surface lectins and cadherin. |
Protein Name | Olfactomedin-4Olm4Antiapoptotic Protein Gw112G-Csf-Stimulated Clone 1 ProteinHgc-1Holfd |
Database Links | Reactome: R-HSA-6798695 |
Cellular Localisation | SecretedExtracellular SpaceMitochondrionSubcellular Location Is Not Clearly Defined: Has Been Shown To Be SecretedBut Also In The MitochondrionCytoplasm And Plasma Membrane And In The Nucleus |
Alternative CLIA Names | Olfactomedin-4 CLIA kitOlm4 CLIA kitAntiapoptotic Protein Gw112 CLIA kitG-Csf-Stimulated Clone 1 Protein CLIA kitHgc-1 CLIA kitHolfd CLIA kitOLFM4 CLIA kitGW112 CLIA kitUNQ362 CLIA kitPRO698 CLIA kit |
Specificity | This kit recognizes Human OLFM4 in samples. No significant cross-reactivity or interference between Human OLFM4 and analogues was observed. |
Reproducibility | Both intra-CV and inter-CV are |
Information sourced from Uniprot.org
Item | Specifications | Storage |
Micro CLIA Plate (Dismountable) | 96T: 8 wells ×12 strips strips | -20℃, 6 months |
Reference Standard | 96T: 2 vials 48T: 1 vial | -20℃, 6 months |
Concentrated Biotinylated Detection Ab (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃, 6 months |
Concentrated HRP Conjugate (100×) | 96T: 1 vial, 120 μL 60 μL | -20℃ (Protect from light), 6 months |
Reference Standard & Sample Diluent | 1 vial, 20 mL | 2-8°C, 6 months |
Biotinylated Detection Ab Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
HRP Conjugate Diluent | 1 vial, 14 mL | 2-8°C, 6 months |
Concentrated Wash Buffer (25×) | 1 vial, 30 mL | 2-8°C, 6 months |
Substrate Reagent A | 1 vial, 5 mL | 2-8℃ (Protect from light) |
Substrate Reagent B | 1 vial, 5 mL | 2-8℃ (Protect from light) |
Plate Sealer | 5 pieces | |
Manual | 1 copy | |
Certificate of Analysis | 1 copy | |
Sample Type | Range (%) | Average Recovery (%) |
Serum(n=8) | 89-103 | 94 |
EDTA plasma(n=8) | 97-112 | 105 |
Cell culture media(n=8) | 98-115 | 106 |
| Intra-assay Precision | Intra-assay Precision | Intra-assay Precision | Inter-assay Precision | Inter-assay Precision | Inter-assay Precision |
Sample | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 |
n | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
Mean (pg/mL) | 51.90 | 124.26 | 497.52 | 55.22 | 123.08 | 477.90 |
Standard deviation | 6.71 | 10.66 | 35.97 | 6.27 | 11.15 | 36.89 |
CV (%) | 12.93 | 8.58 | 7.23 | 11.35 | 9.06 | 7.72 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance